Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation

Blood

Volumn 122, Issue 18, 2013, Pages 3116-3121

  Schneidawind, Dominik ^a   Pierini, Antonio ^a   Negrin, Robert S ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Center for Clinical Sciences Research Building   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL POPULATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL (TOPIC); DIFFUSE LARGE B CELL LYMPHOMA; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MYELOABLATIVE CONDITIONING; NATURAL KILLER T CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRE T LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ANIMAL; BIOLOGICAL MODEL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGY; PROCEDURES; METHODOLOGY; REVIEW;

ANIMALS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MODELS, IMMUNOLOGICAL; NATURAL KILLER T-CELLS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION IMMUNOLOGY;

EID: 84891590554     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-08-453126     Document Type: Article

References (88)

1. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775-787.
2. Trenado A, Charlotte F, Fisson S, et al. Recipienttype specific CD41CD251 regulatory T cells favor immune reconstitution and control graftversus-host disease while maintaining graftversus-leukemia. J Clin Invest. 2003;112(11): 1688-1696.
3. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3): 1151-1164.
4. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609): 1057-1061.
5. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001; 27(1):68-73.
6. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27(1): 20-21.
7. Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001; 27(1):18-20.
8. Andersson J, Tran DQ, Pesu M, et al. CD41 FoxP31 regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med. 2008;205(9):1975-1981.
9. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450(7169):566-569.
10. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(1)CD25(1) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001;194(5):629-644.
11. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006;212(1):28-50.
12. Rubtsov YP, Rasmussen JP, Chi EY, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008;28(4):546-558.
13. Cao X, Cai SF, Fehniger TA, et al. Granzyme B and perforin are important for regulatory T cellmediated suppression of tumor clearance. Immunity. 2007;27(4):635-646.
14. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204(6):1257-1265.
15. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD41CD251 regulatory cells involves a granzyme B-dependent, perforinindependent mechanism. J Immunol. 2005; 174(4):1783-1786.
16. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood. 2004;104(9):2840-2848.
17. Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4): 503-513.
18. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp31 regulatory T cell function. Science. 2008;322(5899):271-275.
19. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(1)CD25(1) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196(3):401-406.
20. Edinger M, Hoffmann P, Ermann J, et al. CD41 CD251 regulatory T cells preserve graft-versustumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150.
21. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(1)CD25(1) regulatory T cells suppress lethal acute graftversus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389-399.
22. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(1)CD25(1) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10):3493-3499.
23. Nguyen VH, Zeiser R, Dasilva DL, et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood. 2007;109(6):2649-2656.
24. Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M. Large-scale in vitro expansion of polyclonal human CD4(1)CD25high regulatory T cells. Blood. 2004;104(3):895-903.
25. Levings MK, Sangregorio R, Roncarolo MG. Human cd25(1)cd4(1) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med. 2001;193(11):1295-1302.
26. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD41CD251 FoxP31 regulatory T cells. Blood. 2005;105(12): 4743-4748.
27. Hippen KL, Merkel SC, Schirm DK, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med. 2011;3(83): 83ra41.
28. Hoffmann P, Eder R, Boeld TJ, et al. Only the CD45RA1 subpopulation of CD41CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood. 2006; 108(13):4260-4267.
29. Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, et al. A functionally specialized population of mucosal CD1031 DCs induces Foxp31 regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. 2007; 204(8):1757-1764.
30. Walker MR, Carson BD, Nepom GT, Ziegler SF, Buckner JH. De novo generation of antigenspecific CD41CD251 regulatory T cells from human CD41CD25-cells. Proc Natl Acad Sci USA. 2005;102(11):4103-4108.
31. Walker MR, Kasprowicz DJ, Gersuk VH, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD41CD25-T cells. J Clin Invest. 2003;112(9):1437-1443.
32. Hill JA, Feuerer M, Tash K, et al. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity. 2007;27(5):786-800.
33. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD41FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood. 2007;110(8):2983-2990.
34. Kim YC, Bhairavabhotla R, Yoon J, et al. Oligodeoxynucleotides stabilize Heliosexpressing Foxp31 human T regulatory cells during in vitro expansion. Blood. 2012;119(12): 2810-2818.
35. Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood. 2009; 114(18):3727-3735.
36. Lal G, Zhang N, van der Touw W, et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol. 2009; 182(1):259-273.
37. Polansky JK, Schreiber L, Thelemann C, et al. Methylation matters: binding of Ets-1 to the demethylated Foxp3 gene contributes to the stabilization of Foxp3 expression in regulatory T cells. J Mol Med (Berl). 2010;88(10):1029-1040.
38. Weiss JM, Bilate AM, Gobert M, et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp31 T reg cells. J Exp Med. 2012;209(10): 1723-1742.
39. Yadav M, Louvet C, Davini D, et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med. 2012;209(10):1713-1722.
40. Allan SE, Crome SQ, Crellin NK, et al. Activationinduced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol. 2007;19(4):345-354.
41. Nishikawa H, Jäger E, Ritter G, Old LJ, Gnjatic S. CD41 CD251 regulatory T cells control the induction of antigen-specific CD41 helper T cell responses in cancer patients. Blood. 2005;106(3): 1008-1011.
42. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD251CD41 T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163(10): 5211-5218.
43. Jones SC, Murphy GF, Korngold R. Posthematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant. 2003; 9(4):243-256.
44. Casares N, Rudilla F, Arribillaga L, et al. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol. 2010;185(9):5150-5159.
45. Klages K, Mayer CT, Lahl K, et al. Selective depletion of Foxp31 regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 2010;70(20): 7788-7799.
46. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921-3928.
47. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3): 1061-1070.
48. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(1) CD25(1) CD4(1) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201(5): 723-735.
49. Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD41 CD251Foxp31 regulatory T cells. Blood. 2011; 118(8):2342-2350.
50. Zeiser R, Leveson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition on CD41CD251Foxp31 regulatory T cells compared with conventional CD41 T cells. Blood. 2008;111(1):453-462.
51. Zorn E, Nelson EA, Mohseni M, et al. IL-2 regulates FOXP3 expression in human CD41 CD251 regulatory T cells through a STATdependent mechanism and induces the expansion of these cells in vivo. Blood. 2006; 108(5):1571-1579.
52. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055-2066.
53. Trzonkowski P, Bieniaszewska M, Júscińska J, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD41CD251CD127-T regulatory cells. Clin Immunol. 2009;133(1): 22-26.
54. Bacchetta R, Bigler M, Touraine JL, et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med. 1994;179(2):493-502.
55. Groux H, O'Garra A, Bigler M, et al. A CD41 T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997; 389(6652):737-742.
56. Vieira PL, Christensen JR, Minaee S, et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD41CD251 regulatory T cells. J Immunol. 2004;172(10):5986-5993.
57. Pot C, Apetoh L, Kuchroo VK. Type 1 regulatory T cells (Tr1) in autoimmunity. Semin Immunol. 2011;23(3):202-208.
58. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol. 2007; 7(8):585-598.
59. Gregori S, Roncarolo MG, Bacchetta R. Methods for in vitro generation of human type 1 regulatory T cells. Methods Mol Biol. 2011;677:31-46.
60. Gregori S, Tomasoni D, Pacciani V, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood. 2010;116(6): 935-944.
61. Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt R, Roncarolo MG. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol. 2001; 166(9):5530-5539.
62. Gagliani N, Magnani CF, Huber S, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med. 2013;19(6):739-746.
63. Baecher-Allan C, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol. 2006;176(8): 4622-4631.
64. Ermann J, Hoffmann P, Edinger M, et al. Only the CD62L1 subpopulation of CD41CD251 regulatory T cells protects from lethal acute GVHD. Blood. 2005;105(5):2220-2226.
65. Shimoda M, Mmanywa F, Joshi SK, et al. Conditional ablation of MHC-II suggests an indirect role for MHC-II in regulatory CD4 T cell maintenance. J Immunol. 2006;176(11): 6503-6511.
66. Taylor PA, Panoskaltsis-Mortari A, Swedin JM, et al. L-Selectin(hi) but not the L-selectin(lo) CD41251 T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood. 2004; 104(12):3804-3812.
67. Masteller EL, Tang Q, Bluestone JA. Antigenspecific regulatory T cells-ex vivo expansion and therapeutic potential. Semin Immunol. 2006; 18(2):103-110.
68. Tang Q, Henriksen KJ, Bi M, et al. In vitroexpanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004; 199(11):1455-1465.
69. Veerapathran A, Pidala J, Beato F, Yu XZ, Anasetti C. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood. 2011;118(20):5671-5680.
70. Meyer EH, Hsu AR, Liliental J, et al. A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graftversus-host disease. Blood. 2013;121(24): 4955-4962.
71. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25: 297-336.
72. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today. 2000;21(11):573-583.
73. Haraguchi K, Takahashi T, Matsumoto A, et al. Host-residual invariant NK T cells attenuate graftversus-host immunity. J Immunol. 2005;175(2): 1320-1328.
74. Kim JH, Choi EY, Chung DH. Donor bone marrow type II (non-Valpha14Jalpha18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-gamma and IL-4. J Immunol. 2007; 179(10):6579-6587.
75. Leveson-Gower DB, Olson JA, Sega EI, et al. Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. Blood. 2011;117(11): 3220-3229.
76. Chaidos A, Patterson S, Szydlo R, et al. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood. 2012;119(21):5030-5036.
77. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versushost disease reveal sequential infiltration of T-cell subsets. Blood. 2005;106(3):1113-1122.
78. Lan F, Zeng D, Higuchi M, Higgins JP, Strober S. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versushost disease: the role of CD1-reactive natural killer T cells. Biol Blood Marrow Transplant. 2003; 9(6):355-363.
79. Pillai AB, George TI, Dutt S, Strober S. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD41CD251 Foxp31 T regulatory cells that protects against graft-versus-host disease. Blood. 2009;113(18): 4458-4467.
80. Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med. 2005;353(13):1321-1331.
81. Kohrt HE, Turnbull BB, Heydari K, et al. TLI and ATG conditioning with low risk of graft-versushost disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009;114(5): 1099-1109.
82. Messina G, Giaccone L, Festuccia M, et al; Gruppo Italiano Trapianti di Midollo. Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies. Biol Blood Marrow Transplant. 2012;18(10): 1600-1607.
83. Duramad O, Laysang A, Li J, Ishii Y, Namikawa R. Pharmacologic expansion of donor-derived, naturally occurring CD4(1)Foxp3(1) regulatory T cells reduces acute graft-versushost disease lethality without abrogating the graft-versus-leukemia effect in murine models. Biol Blood Marrow Transplant. 2011;17(8): 1154-1168.
84. Higuchi M, Zeng D, Shizuru J, et al. Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion. J Immunol. 2002;169(10): 5564-5570.
85. Strober S, Modry DL, Hoppe RT, et al. Induction of specific unresponsiveness to heart allografts in mongrel dogs treated with total lymphoid irradiation and antithymocyte globulin. J Immunol. 1984;132(2):1013-1018.
86. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med. 2008;358(4):362-368.
87. Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S. Induced immune tolerance for kidney transplantation. N Engl J Med. 2011; 365(14):1359-1360.
88. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant. 2012;12(5): 1133-1145.